'Chang­ing the whole game of drug dis­cov­ery': Leg­endary R&D vet Roger Perl­mut­ter leaps back in­to work as a biotech CEO

Roger Perl­mut­ter needs no in­tro­duc­tion to any­one re­mote­ly in­volved in bio­phar­ma. As the R&D chief first at Am­gen and then Mer­ck, he’s built a stel­lar rep­u­ta­tion and a pro­lif­ic ca­reer steer­ing new drugs to­ward the mar­ket for every­thing from can­cer to in­fec­tious dis­eases.

But for years, he’s al­so held a less known ti­tle: sci­ence part­ner at The Col­umn Group, where he’s reg­u­lar­ly con­sult­ed about the var­i­ous ideas the VCs had for new star­tups.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN